Hemogenyx Pharmaceuticals (UK) Performance
| HEMO Stock | 343.40 20.90 6.48% |
The company retains a Market Volatility (i.e., Beta) of -1.19, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Hemogenyx Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Hemogenyx Pharmaceuticals is expected to outperform it. At this point, Hemogenyx Pharmaceuticals has a negative expected return of -0.51%. Please make sure to check out Hemogenyx Pharmaceuticals' total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Hemogenyx Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hemogenyx Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:400 | Last Split Date 2024-12-13 |
1 | Hemogenyx Pharmaceuticals PLC Announces Notice of Extraordinary General Meeting - Yahoo Finance | 11/22/2024 |
2 | Hemogenyx Pharmaceuticals shareholders approve share restructure - Investing.com | 12/09/2024 |
3 | Hemogenyx Pharmaceuticals Sets New 12-Month Low - Heres What Happened - MarketBeat | 12/17/2024 |
| Begin Period Cash Flow | 2.5 M |
Hemogenyx |
Hemogenyx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 59,440 in Hemogenyx Pharmaceuticals PLC on September 23, 2024 and sell it today you would lose (25,100) from holding Hemogenyx Pharmaceuticals PLC or give up 42.23% of portfolio value over 90 days. Hemogenyx Pharmaceuticals PLC is generating negative expected returns and assumes 8.0416% volatility on return distribution over the 90 days horizon. Simply put, 71% of stocks are less volatile than Hemogenyx, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Hemogenyx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hemogenyx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hemogenyx Pharmaceuticals PLC, and traders can use it to determine the average amount a Hemogenyx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0632
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HEMO |
Estimated Market Risk
| 8.04 actual daily | 71 71% of assets are less volatile |
Expected Return
| -0.51 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hemogenyx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hemogenyx Pharmaceuticals by adding Hemogenyx Pharmaceuticals to a well-diversified portfolio.
Hemogenyx Pharmaceuticals Fundamentals Growth
Hemogenyx Stock prices reflect investors' perceptions of the future prospects and financial health of Hemogenyx Pharmaceuticals, and Hemogenyx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hemogenyx Stock performance.
| Return On Equity | -1.56 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 13.18 M | ||||
| Shares Outstanding | 3.5 M | ||||
| Price To Book | 3.93 X | ||||
| EBITDA | (5.73 M) | ||||
| Net Income | (6.69 M) | ||||
| Total Debt | 2.95 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (6.11 M) | ||||
| Earnings Per Share | (2.00) X | ||||
| Total Asset | 6.11 M | ||||
| Retained Earnings | (23.8 M) | ||||
About Hemogenyx Pharmaceuticals Performance
Assessing Hemogenyx Pharmaceuticals' fundamental ratios provides investors with valuable insights into Hemogenyx Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Hemogenyx Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Hemogenyx Pharmaceuticals is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Hemogenyx Pharmaceuticals performance evaluation
Checking the ongoing alerts about Hemogenyx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hemogenyx Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hemogenyx Pharmaceuticals generated a negative expected return over the last 90 days | |
| Hemogenyx Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (6.69 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hemogenyx Pharmaceuticals generates negative cash flow from operations | |
| Latest headline from news.google.com: Hemogenyx Pharmaceuticals Sets New 12-Month Low - Heres What Happened - MarketBeat |
- Analyzing Hemogenyx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hemogenyx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Hemogenyx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hemogenyx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hemogenyx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hemogenyx Pharmaceuticals' stock. These opinions can provide insight into Hemogenyx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.